TLDR: Regulated-industry startups in healthtech, insurtech, legaltech, and compliance-tech are capturing an outsized share of European Series B capital because of regulatory complexity, and for precisely that reason: the compliance burden that compresses early-stage margins converts, by Series B, into durable switching costs, cornered datasets, and strategic acquisition premiums that standard software-as-a-service (SaaS) valuation frameworks systematically understate.
European Series B Is at an All-Time Record, and Regulated Verticals Are Setting the Pace
European Series B median valuations reached €181 million in H1 2025, a 156 percent year-on-year increase and an all-time record, according to Silverpeak’s Q2 2025 European Series B and C Financing Report. Capital invested at the Series B stage rose 46 percent against H2 2024, and rounds above €50 million reached a 30-month high. Within that surge, regulated verticals set the pace. European digital health attracted $6.2 billion in 2025, a 10.3 percent increase year-on-year per Nelson Advisors’ 2026 HealthTech analysis.
European insurtech deal count fell from 164 rounds in 2023 to 75 in 2024, yet total capital dropped only from $2.2 billion to $1.7 billion per the MAPFRE-Dealroom State of Global Insurtech 2024 report. That ratio, fewer deals carrying preserved capital, signals concentration around high-conviction, barrier-protected bets rather than a retreat from the sector. The structural reason is that regulated-industry companies arrive at Series B with a fundamentally different risk architecture than horizontal SaaS peers: the compliance overhead that delayed early growth has become, by the time of the B-round, a set of compounding competitive moats.
Regulated Moats Activate Three of Hamilton Helmer’s 7 Powers Simultaneously
Hamilton Helmer’s 7 Powers framework identifies the structural sources of durable competitive advantage. Regulated-industry startups that have achieved market authorisation activate at least three simultaneously: Switching Costs, Cornered Resource, and Process Power.
Switching Costs in regulated verticals run materially higher than in horizontal software. GrowthSpree’s 2026 B2B SaaS vertical benchmarks record Vertical SaaS at 112 percent median NRR with 9 percent annual churn, against 100 percent NRR and 22 percent annual churn for general marketing technology categories, a gap the report attributes to industry and regulatory stickiness. The mechanism is embedded in technical architecture: a regulated-industry customer that has built workflows around a vendor’s certified product must re-certify those workflows with the relevant regulator before any replacement can go live.
hyperexponential, the UK insurance-pricing platform, illustrates the mechanism precisely. Its $73 million Series B in January 2024, led by Battery Ventures with Andreessen Horowitz (a16z) co-investing through partner Angela Strange, came after the platform had embedded itself in the pricing and underwriting workflows of major insurers including Aviva, HDI, and Conduit Re. An insurer seeking to move to a competing platform must re-certify its pricing models with its regulator before the switch takes effect. Highland Europe’s documentation of the round confirms the business was profitable at raise and had delivered 10x growth since Series A.
Cornered Resource applies when a company accumulates a proprietary dataset that competitors require years and equivalent operational investment to replicate. Neko Health, the Swedish preventive-health scanning company co-founded by Daniel Ek, raised $260 million in its Series B in January 2025 at a $1.8 billion valuation, led by Lightspeed Venture Partners. Its longitudinal full-body scan dataset, accumulated through clinically operating its CE-marked full-body scanning technology across European sites, constitutes a Cornered Resource: a competitor entering today requires years of clinical operations to accumulate a comparable scan library. TechCrunch’s coverage of the round confirms the valuation and Lightspeed’s lead position.
Process Power accrues when the operational complexity of achieving and maintaining certification becomes a competitive advantage in its own right. The a16z discussion on healthcare compliance codification frames this directly: the organisation that has operationalised regulatory compliance at scale runs a process that competitors find prohibitively expensive to replicate and that strategic acquirers pay a premium to absorb.
Standard SaaS Metrics Produce a Double Pricing Error on Regulated-Industry Companies
A generalist venture capital (VC) investor applying standard SaaS metrics to a regulated-industry Series B candidate produces two simultaneous pricing errors: an understated entry valuation and an understated exit multiple. This double error is the structural opportunity that specialist investors are currently exploiting in European regulated verticals, and it is the original synthesis that distinguishes a regulatory-infrastructure thesis from a standard vertical-SaaS thesis.
On the entry side, the generalist observes a 12-to-24-month enterprise procurement cycle and a customer acquisition cost (CAC) that appears elevated against standard benchmarks. High Alpha’s SaaS Benchmarks 2024 and OpenView’s SaaS benchmarks, covering 800-plus companies, place the median SaaS net revenue retention (NRR) at 110 percent. A regulated-industry business with certified workflows embedded in customer operations delivers well above that figure. Nelson Advisors’ 2026 HealthTech Series B benchmarks set best-in-class thresholds at NRR above 120 percent, annual recurring revenue (ARR) growth above 150 percent year-on-year, and a burn multiple below 1.5x. Bessemer Venture Partners’ 50-company health-tech database records an average net dollar revenue retention (NDRR) of 140 percent for tech-enabled services. GrowthSpree’s 2026 vertical benchmarks record cybersecurity NRR at 118 percent with 8 percent annual churn, reflecting the mission-critical, low-churn characteristics common to compliance-embedded software categories.
The slow revenue ramp that a generalist reads as underperformance is the identical mechanism producing the elevated retention: customers that invested 12-to-24 months in procurement and integration carry the highest cost of switching away.
On the exit side, the generalist applies a standard SaaS revenue multiple and misses the strategic acquirer market. Nelson Advisors records MedTech (medical technology) exit multiples of 3.5x to 5.5x revenue and 11x to 14x EBITDA (earnings before interest, taxes, depreciation, and amortisation), with AI-native healthtech commanding 6x to 8x revenue and above. The acquirer for these companies is typically a regulated incumbent purchasing a regulatory authorisation, a certified workflow, or a proprietary dataset, and that transaction is priced on strategic value rather than financial multiples alone.
The table below sets out the key metric divergences across the two investment profiles.
| Dimension | Standard SaaS (Horizontal) | Regulated-Industry Vertical |
|---|---|---|
| Sales Cycle | 3 to 6 months | 6 to 18 months (procurement includes regulatory alignment) |
| Median NRR | 110% (High Alpha / OpenView 2024, 800+ companies) | 120%+ best-in-class; 140% NDRR tech-enabled services (Bessemer 50-company database) |
| Primary Competitive Moat | Network effects, product depth, integrations | Regulatory authorisation + certified workflow embed + proprietary longitudinal dataset (all three 7 Powers active) |
| CAC Payback Benchmark | 12 months (standard SaaS rule of thumb) | 24 to 36 months gross; offset by 120%+ NRR over 5-to-7-year lifetime value (LTV) |
| Switching Cost Index | Baseline (1x) | 112% median NRR / 9% annual churn vs 100% / 22% (GrowthSpree 2026); certified-workflow replacement requires regulatory re-certification before switch takes effect |
| Primary Exit Path | IPO or strategic acquisition at revenue multiple | Strategic acquisition by regulated incumbent buying the authorisation, workflow, or dataset |
| Exit Revenue Multiple | 4x to 8x revenue (Bessemer State of the Cloud 2024) | 3.5x to 5.5x revenue / 11x to 14x EBITDA (MedTech); 6x to 8x+ revenue (AI-native HealthTech); source: Nelson Advisors 2026 |
| Regulatory Certification Treatment | Applicable in narrow categories; minimal impact on valuation | Income-statement cost (accounting) vs. balance-sheet asset (economic): the gap between these two treatments is the pricing inefficiency that specialist investors capture |
Sources: High Alpha / OpenView SaaS Benchmarks 2024; Bessemer Venture Partners Health Tech and State of the Cloud 2024; Nelson Advisors 2026 HealthTech Series B analysis; GrowthSpree B2B SaaS Benchmarks 2026.
The Insurance Carriers Demonstrate the Compounding Effect at Scale
Alan raised €40 million in its Series B in 2019 as an ACPR (Autorité de contrôle prudentiel et de résolution) licensed health insurer. That licence established a structural position that subsequent capital alone was insufficient for a new entrant to replicate. Subsequent growth compounded on a regulated foundation: by March 2026, Alan reached a €5 billion valuation, approximately 125 times the size of its 2019 Series B round over seven years.
Marshmallow, the UK motor insurer specialising in migrant communities, raised $85 million in its Series B in 2021 and followed with a $90 million raise in April 2025 at a $2 billion-plus valuation. The FCA (Financial Conduct Authority) carrier licence is central to both rounds: Marshmallow’s proprietary risk dataset, accumulated through regulated underwriting operations and growing with every policy written, is the compounding asset that the licence makes possible.
Lassie, the Swedish pet insurer, raised $25 million in its Series B in November 2023 led by Balderton Capital. Operating under Swedish FSA (Finansinspektionen) authorisation, Lassie demonstrates that the moat logic applies at sub-scale: the regulatory licence is a structural barrier that precedes any revenue metric in the investment analysis and that a new entrant must replicate in regulatory time, not calendar time.
The shared characteristic across Alan, Marshmallow, and Lassie is that the regulatory authorisation functions as an economic asset even when accounting standards classify the cost of obtaining it as an operating expense. The cost of the licence is sunk; the barrier it creates is ongoing and self-reinforcing. Each policy written deepens the risk dataset and widens the gap between the incumbent carrier and any potential challenger.
2026 Regulatory Transitions Widen the Gap Between Certified and Uncertified Operators
The European regulatory environment in 2026 is producing a structural acceleration of the bifurcation between certified operators and those still in the authorisation queue. Nelson Advisors’ concept of “Regulatory Darwinism” in its 2026 HealthTech analysis captures the mechanism precisely: “Regulatory status has surpassed traditional financial metrics to become the single most critical filter for acquisition and investment.” Three enforcement events drive this in 2026: MDR (Medical Device Regulation) and IVDR (In Vitro Diagnostic Regulation) full enforcement in May 2026, EU AI Act (Artificial Intelligence Act) enforcement for high-risk AI systems commencing August 2026, and EUDAMED (European Database on Medical Devices) full-mandate compliance in May 2026.
Each enforcement event eliminates operators that have deferred compliance and raises the cost of entry for new ones. A Series B company carrying MDR or EU AI Act compliance into this environment holds a certification that a competitor must spend 18-plus months and material capital to replicate before it can serve the same customer base.
Forum VC’s analysis of AI compliance opportunities identifies this as a systematic value-creation vector: compliance infrastructure that functioned as a cost centre becomes a revenue-protecting competitive barrier as the regulatory perimeter expands and the field of qualified competitors narrows. Flywheel Advisors’ framework on regulatory compliance as a competitive weapon reaches the same conclusion for enterprise procurement: compliance certifications function as high-friction differentiators in the exact sales environment where regulated-industry Series B companies operate.
The a16z argument for healthtech infrastructure investment frames the venture thesis from the supply side: durable infrastructure in regulated markets requires a regulated foundation, and returns accrue to those who established that foundation earliest. Bessemer’s State of the Cloud 2024 documents the broader SaaS retention dynamic, and the regulated-industry premium above the SaaS median is persistent across Bessemer’s tracked cohorts across multiple years. The Insurtech4Good analysis of the European tech landscape confirms that European fintech and insurtech capital is bifurcating between commodity distribution plays and regulatory-infrastructure businesses, with concentration on the latter.
The Workflow-Embeds-Compliance Compounding Cycle: A Four-Phase Model
The analytical synthesis distinguishing regulated-industry Series B investment from standard SaaS is what the Kainjoo capital-markets framework identifies as the Workflow-Embeds-Compliance compounding cycle, operating in four sequential phases.
Phase one: the company incurs the compliance cost to obtain market authorisation. This cost flows through the income statement and depresses early-stage margins. That compression is the mechanism producing generalist undervaluation at entry, and it is transient.
Phase two: the company embeds its certified product in the regulated workflows of large customers. Vendep Capital’s analysis of vertical SaaS moats makes the argument that workflow integration is the most durable form of competitive moat in vertical software, separate from and additive to any data advantage. The certification is the precondition for that workflow embedding.
Phase three: workflow integration raises the switching cost to the point where customer retention becomes structurally robust, driving the 120-percent-plus NRR that characterises best-in-class regulated-industry Series B candidates per Nelson Advisors’ 2026 HealthTech Series B benchmarks. The slow procurement cycle that appeared to be a weakness at Series A now reveals itself as a selection mechanism for the highest-retention customer cohort.
Phase four: the operational data accumulated through the embedded workflow generates a proprietary dataset that improves the certified product, reinforcing the Cornered Resource moat and the Switching Cost simultaneously. The moat widens autonomously as deployment scales.
hyperexponential’s position across its major-insurer client base demonstrates all four phases in a single company: regulatory embedding of pricing models creates the switching cost, and accumulation of pricing performance data across that premium base creates a dataset that a new entrant requires equivalent deployment scale to access. The Series B valuation reflected phases three and four in combination, and that is precisely the reading that standard SaaS frameworks miss.
What the Investment Thesis Actually Requires: Four Diligence Departures from Standard SaaS Practice
Investors assessing regulated-industry Series B opportunities in Europe require a purpose-built diligence framework departing from standard SaaS practice across four specific dimensions.
Procurement-cycle-adjusted CAC. A 12-to-18-month sales cycle for a regulatory-embedded product produces a CAC that appears elevated on a gross basis. The correct analytical lens is lifetime value (LTV) against a 120-percent-plus NRR over a five-to-seven-year customer lifetime. A 24-to-36-month CAC payback with 140 percent NDRR is a structurally superior position to a 12-month payback with 100 percent NRR when compounded over equivalent holding periods.
Regulatory-authorisation asset valuation. The cost of obtaining and maintaining certification is an economic capital asset: it creates a barrier that a competitor must spend to replicate and that an acquirer must pay a premium to absorb. Treating this as an operating expense understates intrinsic value at every funding stage and is the primary mechanism through which generalist VC arrives at systematically low entry indications in this sector.
Acquirer-market exit modelling. The primary exit for a regulated-industry Series B in Europe is acquisition by a regulated incumbent in a strategic transaction priced at a compliance premium above standard revenue multiples. The initial public offering (IPO) path exists as a secondary scenario. Portfolio construction and fund-life assumptions must account for a five-to-eight-year exit horizon calibrated to the strategic acquirer cycle, which differs from the three-to-five-year IPO horizon that standard SaaS fund modelling assumes.
NRR as the lead qualification metric. Nelson Advisors’ Series B benchmarks place NRR above 120 percent as the primary qualification threshold, ahead of ARR growth rate. A regulated-industry business with 100 percent ARR growth and 125 percent NRR represents a structurally stronger Series B candidate than one with 200 percent ARR growth and 105 percent NRR, because the retention structure of the former compounds more durably over the expected hold period.
Allegory Capital, which concentrates on deal-side and capital-markets strategy for regulated industries, applies this four-dimension framework to European capital-raising mandates where standard SaaS lenses produce systematically low indications and entry valuations that leave value on the table for founders and their existing investors.
Regulatory Certification as a Balance-Sheet Asset: The Central Reframing
The core analytical contribution of this analysis is a reframing of regulatory certification from income-statement cost to balance-sheet asset. Under standard accounting treatment, the cost of obtaining MDR certification, FCA authorisation, or ACPR licensing flows through the income statement as an operating expense. The economic reality is distinct: certification creates a durable, competition-restricting barrier that generates attributable future cash flows, meeting the economic definition of an asset even when accounting standards classify the outlay as a period cost.
The valuation implications are material and systematic. A company that has spent €5 million obtaining an EU AI Act high-risk AI system certification holds a competitive position that a challenger must invest an equivalent sum and 18-plus months to replicate. That certification carries a net present value (NPV) that remains entirely absent from the income statement, invisible to any generalist investor reading only the P&L. When investors adjust for this, both the entry valuation for a certified regulated-industry Series B and the exit multiple implied by strategic acquisition pricing rise, and they rise together. The simultaneous understatement of both figures is the pricing inefficiency that regulatory-specialist investors are capturing in European markets in 2026.
The Series B data confirms the thesis in aggregate. Capital concentrates in regulated industries, median valuations are at all-time records, and the firms leading those rounds carry analytical frameworks capable of reading regulatory authorisation as a compounding asset rather than a compliance cost. The window of pricing efficiency narrows as that recognition spreads through the broader VC community, which is precisely why the simultaneous enforcement of MDR, EU AI Act, and EUDAMED across 2026 constitutes a structural and time-limited entry point for investors already equipped with the right thesis.
References
- Silverpeak LLP, “Q2 2025 European Series B & C Financing Report”: https://www.silverpeakib.com/wp-content/uploads/2025/07/Silverpeak-Q2-2025-European-Series-BC-Rounds.pdf
- Nelson Advisors / healthcare.digital, “Key Metrics for a HealthTech and MedTech Company to Raise a Series B Round in Europe” (May 2026): https://www.healthcare.digital/single-post/key-metrics-for-a-healthtech-and-medtech-company-to-raise-a-series-b-round-in-europe-in-today-s-envi
- hyperexponential, “Series B Announcement” (January 2024): https://www.hyperexponential.com/newsroom/series-b-announcement
- Highland Europe, “hyperexponential Raises $73M Series B”: https://www.highlandeurope.com/hyperexponential-raises-73m-series-b-to-expand-its-mission-critical-insurance-pricing-platform/
- Neko Health, “$260M Series B Announcement” (January 2025): https://www.nekohealth.com/se/en/press/neko-health-raises-260m-series-b
- TechCrunch, “Neko Health $260M Series B” (January 2025): https://techcrunch.com/2025/01/22/neko-the-body-scanning-startup-co-founded-by-spotifys-daniel-ek-snaps-up-260m-at-a-1-8b-valuation/
- TechCrunch, “Lassie $25M Series B” (November 2023): https://techcrunch.com/2023/11/28/as-pet-owners-turn-to-mobile-insurance-apps-lassie-raises-25m-series-b-led-by-balderton/
- GrowthSpree, “B2B SaaS NRR/GRR Benchmarks 2026”: https://www.growthspreeofficial.com/blogs/b2b-saas-nrr-grr-net-gross-revenue-retention-benchmarks-2026-by-acv-stage-vertical
- Hamilton Helmer, “7 Powers: The Foundations of Business Strategy,” Deep Strategy LLC, 2016: https://7powers.com
- Vendep Capital, “Forget the Data Moat: The Workflow Is Your Fortress in Vertical SaaS”: https://www.vendep.com/post/forget-the-data-moat-the-workflow-is-your-fortress-in-vertical-saas
- High Alpha, “SaaS Benchmarks 2024”: https://www.highalpha.com/saas-benchmarks/2024
- OpenView Partners, “SaaS Benchmarks Report 2024”: https://openviewpartners.com/saas-benchmarks/
- Bessemer Venture Partners, “Benchmarks for Growing Health Tech Businesses”: https://www.bvp.com/atlas/benchmarks-for-growing-health-tech-businesses
- a16z, “Super Staffing: Healthcare, Codifying Compliance, Scaling Services”: https://a16z.com/podcast/super-staffing-healthcare-codifying-compliance-scaling-services/
- a16z, “It’s Time to Build HealthTech Infrastructure”: https://a16z.com/its-time-to-build-healthtech-infrastructure/
- Bessemer Venture Partners, “State of the Cloud 2024”: https://www.bvp.com/atlas/state-of-the-cloud-2024
- Insurtech4Good, “State of European Tech Report 2024: Fintech”: https://www.insurtech4good.com/blog/state-of-european-tech-report-2024-fintech/
- EU Startups, “Alan Raises €40 Million Series B,” February 2019: https://www.eu-startups.com/2019/02/parisian-digital-health-insurance-provider-alan-raises-e40-million-series-b/
- TechCrunch, “Health Insurance Startup Alan Reaches €5B Valuation,” March 2026: https://techcrunch.com/2026/03/11/health-insurance-startup-alan-reaches-e5b-valuation/
- MAPFRE / Dealroom, “The State of Global Insurtech 2024”: https://www.mapfre.com/media/The-State-of-Global-Insurtech_-By-Dealroom-Mundi-Ventures-and-MAPFRE.pdf
- TechCrunch, “Marshmallow Insurance $85 Million Series B,” September 2021: https://techcrunch.com/2021/09/07/marshmallow-insurance-85-million/
- TechCrunch, “Marshmallow Raises $90M at $2B+ Valuation,” April 2025: https://techcrunch.com/2025/04/14/marshmallow-the-uk-insurance-startup-for-migrants-raises-90m-at-a-2b-valuation/
- Forum VC, “AI Compliance Opportunities”: https://www.forumvc.com/thought-pieces/ai-compliance-opportunities
- Flywheel Advisors, “Regulatory Compliance Is Your B2B Competitive Weapon”: https://flywheeladvisors.com/articles/business-development-and-corporate-development-for-ventures/42-regulatory-compliance-is-your-b2b-competitive-weapon/
